Regaining Weight After Stopping GLP-1 Drugs

✓ Medically reviewed | Published: | Evidence level: 1A
Trial extensions of semaglutide and tirzepatide show that much of the lost weight tends to return after treatment stops. A Cleveland Clinic analysis reported in the news has examined which follow-up strategies work best, reinforcing that obesity behaves like a chronic condition that needs a long-term plan.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Weight Loss

Quick Facts

STEP 1 extension
About two-thirds regained
SURMOUNT-4 switch to placebo
About 14% regain
Disease model
Chronic, relapsing

Why do people regain weight after stopping GLP-1 drugs?

Quick answer: GLP-1 drugs act on appetite and satiety signaling only while they are in the body, so when treatment stops, hunger and food cravings tend to return and weight often follows.

GLP-1 receptor agonists such as semaglutide and the dual GIP/GLP-1 agonist tirzepatide reduce appetite, slow gastric emptying and shift reward signaling in the brain. These effects depend on continued drug exposure. Once the medication clears, the biological pressures that defend a higher body weight, including increased hunger hormones and a lower resting energy expenditure after weight loss, are no longer offset.

Trial evidence is consistent with this. In the extension of the STEP 1 trial, published in Diabetes, Obesity and Metabolism in 2022, participants who stopped semaglutide regained roughly two-thirds of their lost weight within a year. In SURMOUNT-4, published in JAMA in 2024, adults who were switched from tirzepatide to placebo regained a substantial portion of their weight, while those who continued the drug kept losing. These findings support the view that obesity is a chronic, relapsing disease rather than a problem fixed by a time-limited course of treatment.

What strategies can help maintain weight loss after GLP-1 therapy ends?

Quick answer: Options clinicians study include a gradual dose taper, continued lower-dose maintenance, switching to another anti-obesity medication, and structured nutrition and resistance exercise programs.

A Cleveland Clinic study reported in the news examined which treatment approaches work best for patients who have stopped GLP-1 drugs. The full findings should be read in the original publication. The broader clinical picture points to several approaches. Some patients move to a lower maintenance dose, while others switch to a different anti-obesity medication, for example when cost, supply or side effects drive the decision to stop. Intensive lifestyle support, including protein-adequate diets and resistance training, may help preserve lean mass and make the transition easier.

Clinicians also stress planning the exit before it happens. Monitoring weight, blood pressure, blood glucose and cholesterol after discontinuation can catch rebound early, and re-starting treatment may be appropriate if weight and metabolic markers worsen. Patients should not stop prescribed therapy without discussing it with their care team, particularly if they have type 2 diabetes, because glucose control can deteriorate when treatment ends.

Frequently Asked Questions

Not necessarily all of it, but trial extensions show that many people regain a large share, roughly two-thirds in the STEP 1 extension within a year. Individual results vary with diet, activity and the support in place.

Tapering or moving to a maintenance dose is sometimes used, but the evidence on the best approach is still developing. Decisions should be made with your prescriber.

Resistance training and adequate protein intake help preserve muscle during and after weight loss, and regular activity supports long-term weight maintenance.

References

  1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
  2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
  3. Cleveland Clinic Newsroom. Cleveland Clinic Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs. 2026.